SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne

Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% duri

ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chroni

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks

Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate up

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sab

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will h

Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIP

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointmen

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform a

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company wi

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborati

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging part

Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline,

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcri

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percen

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate up

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne

Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 i

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/down

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and rais

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powerin

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight

Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperfor

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the h

AMD: 15% | AMD To Power Meta AI Expansion With Up To 6 Gigawatts Of Instinct GPUs Under Multi Year A

Vir Biotechnology stock skyrockets after $335 million Astellas deal, strong prostate cancer data, an

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises th

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new data from the ongoing Phase 1 clinical tria

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of ex